D.E. Shaw & Co
AVDL

D.E. Shaw & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

D.E. Shaw & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-132,459
Closed -$2.85M – 4534
2025
Q4 		$2.85M Sell
132,459
-237,170
-64% -$4.6M ﹤0.01% 2761
2025
Q3 		$5.64M Sell
369,629
-67,926
-16% -$884K ﹤0.01% 2103
2025
Q2 		$3.87M Sell
437,555
-57,123
-12% -$502K ﹤0.01% 2224
2025
Q1 		$3.87M Buy
494,678
+185,020
+60% +$1.55M ﹤0.01% 2092
2024
Q4 		$3.25M Buy
309,658
+183,496
+145% +$2.23M ﹤0.01% 2331
2024
Q3 		$1.65M Buy
126,162
+91,290
+262% +$1.39M ﹤0.01% 2864
2024
Q2 		$490K Sell
34,872
-47,237
-58% -$770K ﹤0.01% 3635
2024
Q1 		$1.39M Sell
82,109
-114,445
-58% -$1.7M ﹤0.01% 2884
2023
Q4 		$2.78M Sell
196,554
-352,816
-64% -$4.14M ﹤0.01% 2411
2023
Q3 		$5.66M Sell
549,370
-216,466
-28% -$2.9M 0.01% 1716
2023
Q2 		$12.6M Buy
765,836
+454,546
+146% +$5.91M 0.01% 1154
2023
Q1 		$2.85M Sell
311,290
-32,465
-9% -$267K ﹤0.01% 2417
2022
Q4 		$2.46M Sell
343,755
-8,359
-2% -$58.6K ﹤0.01% 2764
2022
Q3 		$1.76M Buy
352,114
+338,682
+2,521% +$1.86M ﹤0.01% 3110
2022
Q2 		$33K Buy
+13,432
New +$55.1K ﹤0.01% 4909
2021
Q4 		– Sell
-33,041
Closed -$324K – 5390
2021
Q3 		$324K Buy
33,041
+19,405
+142% +$153K ﹤0.01% 4312
2021
Q2 		$92K Buy
+13,636
New +$108K ﹤0.01% 4561
2020
Q4 		– Sell
-20,342
Closed -$103K – 3902
2020
Q3 		$103K Sell
20,342
-76,072
-79% -$553K ﹤0.01% 3702
2020
Q2 		$779K Buy
+96,414
New +$850K ﹤0.01% 3093
2020
Q1 		– Sell
-14,118
Closed -$107K – 3914
2019
Q4 		$107K Buy
+14,118
New +$74.6K ﹤0.01% 3871
2019
Q3 		– Sell
-17,425
Closed -$50K – 3799
2019
Q2 		$50K Sell
17,425
-16,470
-49% -$28.3K ﹤0.01% 3587
2019
Q1 		$49K Sell
33,895
-11,949
-26% -$27K ﹤0.01% 3517
2018
Q4 		$118K Sell
45,844
-21,696
-32% -$73.8K ﹤0.01% 3624
2018
Q3 		$297K Sell
67,540
-106,121
-61% -$573K ﹤0.01% 3365
2018
Q2 		$1.06M Buy
173,661
+78,199
+82% +$549K ﹤0.01% 2665
2018
Q1 		$696K Sell
95,462
-161,517
-63% -$1.42M ﹤0.01% 2727
2017
Q4 		$2.11M Buy
256,979
+2,785
+1% +$26.1K ﹤0.01% 2105
2017
Q3 		$2.67M Sell
254,194
-14,947
-6% -$143K ﹤0.01% 1814
2017
Q2 		$2.97M Buy
269,141
+19,278
+8% +$194K ﹤0.01% 1717
2017
Q1 		$2.42M Buy
249,863
+13,657
+6% +$137K ﹤0.01% 1722
2016
Q4 		$2.45M Buy
236,206
+15,451
+7% +$170K ﹤0.01% 1843
2016
Q3 		$2.74M Buy
220,755
+67,676
+44% +$884K ﹤0.01% 1684
2016
Q2 		$1.64M Buy
153,079
+42,249
+38% +$450K ﹤0.01% 2072
2016
Q1 		$1.22M Buy
110,830
+5,934
+6% +$58.9K ﹤0.01% 2226
2015
Q4 		$1.28M Sell
104,896
-58,719
-36% -$916K ﹤0.01% 2465
2015
Q3 		$2.67M Buy
163,615
+59,078
+57% +$1.3M ﹤0.01% 1877
2015
Q2 		$2.21M Buy
104,537
+32,272
+45% +$579K ﹤0.01% 2123
2015
Q1 		$1.3M Sell
72,265
-589,864
-89% -$9.24M ﹤0.01% 2350
2014
Q4 		$11.3M Sell
662,129
-34,406
-5% -$491K 0.01% 1028
2014
Q3 		$9.97M Buy
696,535
+119,892
+21% +$1.72M 0.01% 1088
2014
Q2 		$8.65M Buy
+576,643
New +$6.96M 0.01% 1209

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

D.E. Shaw & Co's AVDL Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 132,459 shares — an estimated $2.85M sold.

D.E. Shaw & Co first reported a position in AVDL in Q2 2014 and held it in 41 quarters. The position peaked at $12.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 132,459 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.85M.
  • D.E. Shaw & Co first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 41 quarters.
  • D.E. Shaw & Co's Avadel Pharmaceuticals position peaked at $12.6M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.